UNICREDIT BANK/CALL/AMGEN/450/0.1/14.01.26 | Market Closed - BOERSE MUENCHEN 03:41:12 2024-05-17 pm EDT | ||
| 1 EUR | -4.76% |
|
| Current month | +127.27% | ||
| 1 month | +163.16% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 1 | -4.76% |
| 24-05-16 | 1.05 | -7.08% |
| 24-05-15 | 1.13 | +18.95% |
| 24-05-14 | 0.95 | +5.56% |
| 24-05-13 | 0.9 | -8.16% |
Real-time BOERSE MUENCHEN
Last update May 17, 2024 at 03:41 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HD2FAT |
| ISIN | DE000HD2FAT2 |
| Date issued | 2024-02-05 |
| Strike | 450 $ |
| Maturity | 2026-01-14 (607 Days) |
| Parity | 10 : 1 |
| Emission price | 1.23 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.31 € |
|---|---|
| Lowest since issue | 0.34 € |
| Spread | 0.02 € |
| Spread % | 2.00% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
312.5
USD
Average target price
314.1
USD
Spread / Average Target
+0.51%
- Stock Market
- Warrants
- Warrant